The effect of Olanzapine and Sertraline on personality disorder in patients with methadone maintenance therapy

Psychiatria Danubina

Volumn 22, Issue 4, 2010, Pages 544-547

  Jariani, Mojhgan ^a   Saaki, Mandana ^a   Nazari, Hedayat ^a   Birjandi, Mehdi ^a  

^a LORESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Borderline personality disorder; Methadone maintenance therapy; Olanzapine; Sertraline

Indexed keywords

METHADONE; OLANZAPINE; SERTRALINE;

ADULT; AGGRESSION; ANXIETY; ARTICLE; BORDERLINE STATE; CLINICAL ASSESSMENT; DEPRESSION; DRUG DEPENDENCE; DRUG EFFECT; FEMALE; HUMAN; HUMAN RELATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSESSION; PERSONALITY DISORDER; PESSIMISM; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOMATIZATION; TREATMENT DURATION;

ADULT; AGGRESSION; ANALGESICS, OPIOID; ANXIETY; BENZODIAZEPINES; BORDERLINE PERSONALITY DISORDER; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERPERSONAL RELATIONS; MALE; METHADONE; OBSESSIVE BEHAVIOR; QUESTIONNAIRES; SAMPLING STUDIES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SEVERITY OF ILLNESS INDEX; SOMATOFORM DISORDERS; TREATMENT OUTCOME;

EID: 78651263147     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Akerele E & Levin FR: Comparison of olanzapine to risperidone in, comparison of olanzapine to risperidone in abusing with schizophrenia. Am J Addict 2007; 16: 260-268. (Pubitemid 47174581)
2. About Mental Health and Addiction (concurrent Disorders) Centre for Addiction and Mental Health, InformationaboutConcurrentDisorders.Availablefrom: http://www.camh.net/About-Addiction-Mental-Health/ Concurrent-Disorders/index. html. Accessed 8 Feb 2009
3. Bellino S, Paradiso E & Bogetto F: Efficacy and Tolerability of Pharmacotherapies for Borderline Personality Disorder. CNS Drugs 2008; 22: 671-692. (Pubitemid 351950098)
4. Chakroun N, Down J & Swendsen J: Substance use, affective problems and personality traits: test of two association models. Encephale 2004; 30: 564-569.
5. Compton WM 3rd, Cottier LB, Jacobs JL, Ben-Abdallah A& Spitznagel EL: The role of psychiatric disorder in predicting drug dependence treatment outcomes. Am J Psychiatry 2003; 160: 890-895.
6. Damsa C, Adam E, De Gregorio F, Cailhol L, Lejeune J, Lazignac C, et al: Intramuscular olanzapine in patients with borderline personality disorder: an observational study in an emergency room. Gen Hosp Psychiatry 2007; 29: 51-53.
7. Darke S, Williamson A, and Ross J, Teesson M& Lynskey M: Borderline personality disorder, antisocial personality disorder and risk - taking among heroin users: finding from Australian Treatment Outcome study (ATOS). Drug Alcohol Depend 2004; 9074: 77-83.
8. Frei A & Rehm J: Co-morbidity: psychiatric disorder of opiate addicts at entry into heroin-assisted treatment. Psychiatr Prax 2002; 29: 251-257 (Pubitemid 34792865)
9. Gerra G, Di Petta G, D'Amore A, Iannotta P, Bardicchia F, Falorni F, et al: Effects of olanzapine on aggressiveness in heroin dependent patients. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:1291-1298.
10. Gerra G, Zaimovic A, Moi G, Bussandri M, Bubici C, Mossini M, et al: Aggressive responding in abstinent heroin addicts: neuroendocrine and personality correlates. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:129-139. (Pubitemid 37548505)
11. Gerra G, Dipetta G& DAmore A: Combination of olanzapine with opoid agonist in the treatment heroin- addicted patient affected by comorbid schizophrenia spectrum disorder. Clin Neuropharmacol 2007; 30:127-135.
12. Hellerstein DJ, Kocsis JH, Chapman D, Stewart JW& Harrison W: Double-blind comparison of sertraline, Imipramine, and placebo in the treatment of dysthymia: effects on personality. Am J Psychiatry 2000; 157:1436-1444.
13. Hough DW: Low dose olanzapine for self-mutilation behavior in borderline personality disorder. J Clin Psychiatry 2001; 62:296-297. (Pubitemid 32428772)
14. Kathleen T&, Rajita S: Co occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatry 2005; 162:1483-1493.
15. Linehan MM, McDavid JD, Brown MZ, Sayrs JH& Gallop RJ: Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo- controlled pilot study. J Clin Psychiatry 2008; 69:999-1005.
16. Skodol AE, Oldham JM& Gallaher PE: Axis II co morbidity of substance use disorders among patients referred for treatment of personality disorders. Am J Psychiatry 1999; 156: 733-738.
17. Sullivan MD, Edlund MJ, Steffick D& Unutezer J: Regular use of prescribed opioids: association with common psychiatric disorders. Pain 2005; 119: 95-103.
18. Zanarini MC & Frankenberg FR. Olanzapine treatment of female borderline personality disorder patient. J Cli Psychiatry 2001; 62: 849-854.
19. Zanarini MC, Frankenburg FR& Parachini EA: A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004; 65:903-7.